The need for fast-track, high-quality and low-cost studies about the role of the BCG vaccine in the fight against COVID-19

Bacillus Calmette-Guérin (BCG) vaccination is routine and near-universal in many low- and middle-income countries (LMIC). It has been suggested that BCG can have a protective effect on COVID-19 morbidity and mortality. This commentary discusses the limitations of the evidence around BCG and COVID-19...

Full description

Saved in:
Bibliographic Details
Published in:Respiratory research 2020-07, Vol.21 (1), p.178-178, Article 178
Main Authors: Pereira, Marcos, Paixão, Enny, Trajman, Anete, de Souza, Ramon Andrade, da Natividade, Marcio Santos, Pescarini, Julia M, Pereira, Susan Martins, Barreto, Florisneide Rodrigues, Ximenes, Ricardo, Dalcomo, Margareth, Ichihara, Maria Yury, Nunes, Ceuci, Barral-Netto, Manoel, Barreto, Maurício L
Format: Article
Language:English
Subjects:
Absenteeism
Bacillus Calmette-Guerin vaccine
BCG
BCG Vaccine - immunology
BCG Vaccine - therapeutic use
Clinical outcomes
Clinical trials
Clinical Trials as Topic
Coronavirus Infections - mortality
Coronavirus Infections - prevention & control
Coronavirus Infections - therapy
Coronaviruses
Cost-Benefit Analysis
COVID-19
COVID-19 diagnostic tests
Cytokines
Fatalities
Female
Humans
Letter to the Editor
Low income groups
Male
Medical personnel
Morbidity
Mortality
Needs Assessment
Older people
Pandemics
Pandemics - prevention & control
Pneumonia, Viral - mortality
Pneumonia, Viral - prevention & control
Pneumonia, Viral - therapy
Poverty
Prevention
Primary Prevention - methods
Quality Control
Role
Severe acute respiratory syndrome coronavirus 2
Socioeconomic Factors
Survival Analysis
Testing
Tuberculosis
Vaccination
Vaccination - methods
Vaccination - statistics & numerical data
Vaccines
Viral infections
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Bacillus Calmette-Guérin (BCG) vaccination is routine and near-universal in many low- and middle-income countries (LMIC). It has been suggested that BCG can have a protective effect on COVID-19 morbidity and mortality. This commentary discusses the limitations of the evidence around BCG and COVID-19. We argue that higher-quality evidence is necessary to understand the protective effect of the BCG vaccine from existing, secondary data, while we await results from clinical trials currently conducted in different settings.
ISSN:1465-993X
1465-9921
1465-993X
1465-9921
DOI:10.1186/s12931-020-01439-4